Chronic myeloid leukemia (CML) is driven by the BCR-ABL1 fusion protein, formed by a
translocation between chromosomes 9 and 22 that creates the Philadelphia chromosome …

In less than 10 years, the prognosis of chronic myeloid leukaemia has changed from that of
a fatal disease to a disorder amenable simply to lifelong oral medication and compatible …

Patients with chronic myeloid leukemia in chronic phase (CML-CP) resistant/intolerant to≥ 2
tyrosine kinase inhibitors (TKIs) are at high risk of experiencing poor outcomes because of …

Background Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for
patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses …

Purpose Bosutinib is a potent dual SRC/ABL kinase inhibitor approved for adults with
Philadelphia chromosome–positive chronic myeloid leukemia (CML) resistant and/or …

Background Chronic graft-versus-host disease (GVHD) is the leading cause of later illness
and death after allogeneic hematopoietic stem-cell transplantation. We hypothesized that …

Ponatinib has potent activity against native and mutant BCR-ABL1, including BCR-
ABL1T315I. The pivotal phase 2 Ponatinib Ph+ ALL and CML Evaluation (PACE) trial …

The therapeutic armamentarium for chronic myeloid leukaemia (CML) comprises mainly
tyrosine kinase inhibitors (TKIs), with several agents available for frontline treatment, or for …

With the deaths of Janet Rowley and John Goldman in December 2013, the world lost two
pioneers in the field of chronic myeloid leukemia. In 1973, Janet Rowley, unraveled the …

Bosutinib is approved for newly diagnosed Philadelphia chromosome-positive (Ph+) chronic
phase (CP) chronic myeloid leukemia (CML) and for Ph+ CP, accelerated (AP), or blast (BP) …